You are here » Home » Companies » Company Overview » Lasa Supergenerics Ltd

Lasa Supergenerics Ltd.

BSE: 540702 Sector: Health care
NSE: LASA ISIN Code: INE670X01014
BSE 00:00 | 22 Oct 17.45 -0.35
(-1.97%)
OPEN

17.80

HIGH

17.80

LOW

17.35

NSE 00:00 | 22 Oct 17.85 -0.35
(-1.92%)
OPEN

17.40

HIGH

18.20

LOW

17.40

OPEN 17.80
PREVIOUS CLOSE 17.80
VOLUME 7853
52-Week high 36.10
52-Week low 9.48
P/E
Mkt Cap.(Rs cr) 40
Buy Price 17.30
Buy Qty 309.00
Sell Price 18.20
Sell Qty 591.00
OPEN 17.80
CLOSE 17.80
VOLUME 7853
52-Week high 36.10
52-Week low 9.48
P/E
Mkt Cap.(Rs cr) 40
Buy Price 17.30
Buy Qty 309.00
Sell Price 18.20
Sell Qty 591.00

Lasa Supergenerics Ltd. (LASA) - Chairman Speech

Company chairman speech

Dear Fellow Shareholders

It gives me great pleasure to share with you the highlights of our Company'sperformance for the financial yearended March 312018.

Our Company has continued to live up to the dedication and commitment towards servicingthe veterinary API market. The Company is confident to grow with growth driven economyacross the globe customer strengthening and huge opportunity lying within Veterinary.

Our ability to offer a wide range of product portfolio and the right product mixthrough our in-house expertise of catalyst chemistry has made the Company a preferredchoice with many clients. Our teams have been constantly engaging in developing newmolecules at our R&D facility.

At Lasa Supergenerics creating value for all stakeholders including our shareholdershas been a defining element of our identity.

Since the demerger of Lasa Supergenerics Ltd. the Company has delivered goodperformance which a very few Veterinary API manufacturing Indian companies have achieved.The consistency of our performance is the outcome of a fully backward integrated processmodel wherein multiple parameters and metrics work in tandem with financial and operatingperformance to realize sustainable growth for the long-term. The performance isunderpinned by accurate know-how of molecules catalyst chemistry a values-drivenculture efficient capital allocation strong corporate governance and an entrepreneurialspirit.

We are in a state of continuous evolution through a strong drive for improvement whileremaining focussed on quality compliance talent development and effective riskmanagement. Our untarnished track record and veracity in dealing with clients are keyfactors that inspire multiple global collaborations with reputed associates across ourbusinesses.

Today the Company has emerged as:

• Amongst leading API manufacturing players to operate on completely backwardintegrated though catalyst chemistry

• Positioned strongly in the overall Veterinary API marketsglobally

• Among very few Indian companies with specialized R&D facility and adedicated team who has a strong knowledge and experience in catalyst chemistry

The focus of the Company will continue to deliver value to our customers; to backwardintegrate; innovate with new molecules which will ultimately lead to maximization ofshareholder value & return.

Today India is amongst one of the fastest growing major economies in the world butgrowth was muted on account of various factors like policy reform setbacks stress inIndian banking industry and lack of private sector investments amongst others. Thisaffected growth and profitability of companies across sectors.

Seeing the trend continue we have concentrated our efforts on bringing in efficienciesthrough backward integration catalyst chemistry enhancement product development costoptimization and technology enhancement.

We are confident that in the coming years along with the growth in domesticconsumption & growth in economy we will not only capture market share but also growacross India.

FUTURE PLANS

With the Government's focus on growth of manufacturing in India and GST is in place.Globally healthcare spending in terms of percentage to the GDP is rising. The increasingcost of bringing drugs and devices to the market and greater regulatory scrutiny areensuing an increased demand for high-quality information and analytical support.

The global pharmaceutical market recorded yet another year of significance and themarket is likely to expand manyfoldsto us$ 1.4 trillion by 2020.

During the year we started increasingly delivering our products and services in moreefficient manner and we focus on continue doing the same in the coming years.

Going forward we will continue to focus on our existing businesses. We also plan tolaunch some new molecules of API with new product development in the coming year. Wecontinue to build our capacities for future growth.

Human capital remains the core of our success and we have continued and will continueto invest considerable efforts in this direction not only at higher level but till groundlevel. Employee engagement is the main pillar of our growth strategy. I believe that ourexisting talent pool will enable us to outperform our peers and meet our obligations as anorganization to all our stakeholders.

I thank you all for your immense support and continued confidence in the management ofour Company. I also like to thank all our stakeholders - customers employees partnersshareholders business associates and society at large fortheirfaith in us.

ThankYou.